Adjuvant treatment — Competitive Intelligence Brief

Adjuvant treatment (Adjuvant treatment) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immune checkpoint inhibitor. Area: Oncology.

phase 2 Immune checkpoint inhibitor CD137 Oncology Small molecule

Target snapshot

Adjuvant treatment (Adjuvant treatment) — GERCOR - Multidisciplinary Oncology Cooperative Group. This drug works by enhancing the body's immune response to cancer.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Adjuvant treatment TARGET	Adjuvant treatment	GERCOR - Multidisciplinary Oncology Cooperative Group	phase 2	Immune checkpoint inhibitor	CD137
MEDI3250	MEDI3250	AstraZeneca	phase 3	Bispecific antibody; PD-L1/4-1BB bispecific	PD-L1 and 4-1BB (CD137)
Immune Checkpoint Inhibitors	Immune Checkpoint Inhibitors	The Central Hospital of Lishui City	marketed	Immune checkpoint inhibitor
Cisplatin / Carboplatin，Gemcitabine，Cindilimab	Cisplatin / Carboplatin，Gemcitabine，Cindilimab	People's Hospital of Quzhou	marketed	Combination chemotherapy with immune checkpoint inhibitor	DNA (platinum agents, gemcitabine); PD-L1 (cindilimab)
anti-IL-2R	anti-IL-2R	Hoffmann-La Roche	phase 3	Immune checkpoint inhibitor	IL-2R
IN-C006 Peri inj.	IN-C006 Peri inj.	HK inno.N Corporation	phase 3	Immune checkpoint inhibitor	PD-1
Rescue medications for chemotherapy	Rescue medications for chemotherapy	Merck Sharp & Dohme LLC	phase 3	Immune checkpoint inhibitor	PD-1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immune checkpoint inhibitor class)

1. Sun Pharma Advanced Research Company Limited · 2 drugs in this class
2. Brenda Cooper, MD · 1 drug in this class
3. Grace Therapeutics Inc. · 1 drug in this class
4. EMS · 1 drug in this class
5. GERCOR - Multidisciplinary Oncology Cooperative Group · 1 drug in this class
6. Glycotope GmbH · 1 drug in this class
7. Bristol-Myers Squibb · 1 drug in this class
8. HK inno.N Corporation · 1 drug in this class
9. Hanlim Pharm. Co., Ltd. · 1 drug in this class
10. Assistance Publique - Hôpitaux de Paris · 1 drug in this class